Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,000
Closed -$982K 87
2025
Q4
$982K Buy
3,000
+1,000
+50% +$317K 0.26% 68
2025
Q3
$564K Buy
+2,000
New +$580K 0.18% 80
2023
Q3
Sell
-4,000
Closed -$888K 97
2023
Q2
$888K Sell
4,000
-400
-9% -$92.8K 0.47% 41
2023
Q1
$1.06M Buy
+4,400
New +$1.08M 0.65% 34

Other funds holding AMGN

DCF Advisers's AMGN Position: Q1 2026 in Review

DCF Advisers reduced its Amgen (AMGN) stake by 56% in Q1 2026, selling an estimated $2.67M and leaving 6,000 shares worth $2.11M. The position accounts for 0.56% of the portfolio, ranked #41.

DCF Advisers first reported a position in AMGN in Q4 2019 and has held it in 22 quarters since. The position peaked at $4.42M in Q4 2025. 3,130 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • DCF Advisers held 6,000 shares of Amgen worth $2.11M as of Q1 2026.
  • DCF Advisers sold 7,500 Amgen shares in Q1 2026, an estimated $2.67M.
  • Amgen made up 0.56% of DCF Advisers's portfolio in Q1 2026, its #41 holding.
  • DCF Advisers first reported a position in Amgen in Q4 2019 and has held it in 22 quarters since.
  • DCF Advisers's Amgen position peaked at $4.42M in Q4 2025.
  • 3,130 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.